Using Machine Learning to Predict Remission in Patients With Major Depressive Disorder Treated With Desvenlafaxine

• Published in: Canadian journal of psychiatry 2022-01, Vol.67 (1), p.39-47
• Main Authors: Benoit, James R.A., Dursun, Serdar M., Greiner, Russell, Cao, Bo, Brown, Matthew R.G., Lam, Raymond W., Greenshaw, Andrew J.
• Format: Article
• Language: English
• Subjects: Antidepressive Agents - therapeutic use; Depressive Disorder, Major - diagnosis; Desvenlafaxine Succinate - therapeutic use; Humans; Machine Learning; Mental depression; Patients; Regular; Treatment Outcome
• ISSN: 0706-7437; 1497-0015
• DOI: 10.1177/07067437211037141

Background Major depressive disorder (MDD) is a common and burdensome condition that has low rates of treatment success for each individual treatment. This means that many patients require several medication switches to achieve remission; selecting an effective antidepressant is typically a sequential trial-and-error process. Machine learning techniques may be able to learn models that can predict whether a specific patient will respond to a given treatment, before it is administered. This study uses baseline clinical data to create a machine-learned model that accurately predicts remission status for a patient after desvenlafaxine (DVS) treatment. Methods We applied machine learning algorithms to data from 3,399 MDD patients (90% of the 3,776 subjects in 11 phase-III/IV clinical trials, each described using 92 features), to produce a model that uses 26 of these features to predict symptom remission, defined as an 8-week Hamilton Depression Rating Scale score of 7 or below. We evaluated that learned model on the remaining held-out 10% of the data (n = 377). Results Our resulting classifier, a trained linear support vector machine, had a holdout set accuracy of 69.0%, significantly greater than the probability of classifying a patient correctly by chance. We demonstrate that this learning process is stable by repeatedly sampling part of the training dataset and running the learner on this sample, then evaluating the learned model on the held-out instances of the training set; these runs had an average accuracy of 67.0% ± 1.8%. Conclusions Our model, based on 26 clinical features, proved sufficient to predict DVS remission significantly better than chance. This may allow more accurate use of DVS without waiting 8 weeks to determine treatment outcome, and may serve as a first step toward changing psychiatric care by incorporating clinical assistive technologies using machine-learned models.